Clinical Trials Logo

Clinical Trial Summary

There is limited support in primary care for diet and lifestyle, the cornerstones for therapy in clinical practice guidelines. Canadian dietitian services are not covered by provincial health plans and most physicians cite a lack of education, tools and time to counsel on nutrition. To engage healthcare professionals (HCP) and patients in the delivery of nutrition interventions, the investigators have developed the Portfolio Diet mobile application, as a direct translation of clinical practice guidelines for cardiovascular and diabetes risk reduction which recommend the Portfolio Diet, a plant-based dietary pattern of cholesterol-lowering foods. To increase confidence and comfortability in advising patients on the Portfolio Diet, the investigators have developed an HCP-facing toolkit (infographic and video) to communicate information on the Portfolio Diet and Portfolio Diet mobile application. To ensure validity of these resources, the investigators will conduct face and content validation of the HCP-facing toolkit and assess whether it increases HCP knowledge and potential use in practice, and assess HCP perspectives on the Portfolio Diet mobile application.


Clinical Trial Description

Background: As the Canadian population ages, there is an increased risk of cardiovascular disease (CVD) and higher healthcare costs. Thus, there is a need for dietary approaches to target these challenges. Furthermore, with the transition to greater virtual care, innovative technology-based interventions using mobile applications provide an opportunity to engage healthcare professionals (HCP), including family physicians, registered dietitians (RDs), nurses, pharmacists, and patients in delivering nutrition care to save time, provide education, and reduce costs. The Portfolio Diet, an evidence-based therapeutic dietary pattern for CVD risk reduction, is uniquely positioned to test this innovative paradigm. This plant-based dietary pattern of five cholesterol-lowering foods (nuts, legumes, viscous fibre, plant sterols, monounsaturated fat) has been shown to result in the same low-density lipoprotein-cholesterol (LDL-C) and C-reactive protein reductions (CRP) (~30%) as statin therapy in a head-to-head randomized controlled trial. A recent systematic review and meta-analysis. confirmed these effects and also showed benefits on other cardiovascular risk factors including non-high-density lipoprotein-cholesterol (non-HDL-C), apoB, triglycerides, and blood pressure. Prospective cohort studies have also shown that the Portfolio Diet is associated with a lower risk of CVD, particularly coronary heart disease, and type 2 diabetes. These benefits have led to widespread recognition of the Portfolio Diet from major international clinical practice guidelines, including the Canadian Cardiovascular Society (CCS). The investigators recently developed the Portfolio Diet mobile application, as a transformative digitally-enabled health service tool for the translation of current CCS guidelines to manage dyslipidemia and prevent CVD. While the Portfolio Diet is recognized by clinical practice guidelines as a preventive nutrition therapy for CVD, many HCPs remain unaware of the Portfolio Diet and of the Portfolio Diet mobile application. To increase confidence and comfortability in advising patients on the Portfolio Diet, the investigators developed an HCP-facing toolkit (infographic and video) to communicate information on the Portfolio diet and Portfolio Diet app. To ensure validity, the investigators plan to conduct face and content validation of the HCP-facing toolkit and assess whether it increases HCP knowledge and potential use in practice, as well as to assess HCP perspectives of the Portfolio Diet app. Objectives: The primary objective is to face and content validate the HCP-facing toolkit and assess whether it increases HCP knowledge and potential use in practice. The second objective is to conduct a quality improvement assessment of the Portfolio Diet mobile application to evaluate its usability, acceptability, knowledge acquisition and potential use in practice. Methods: Design: Thirty physicians, registered dietitians, and other allied HCP will be recruited from clinics for a 2-phase study to assess face and content validation of the HCP-facing toolkit and usability of the Portfolio Diet mobile application. 15 HCP will participate in each of 2 rounds. In phase 1, 15 HCP with receive the toolkit and a feedback questionnaire. In phase 2, 10 HCPs from phase 1 will be invited to create an account on the Portfolio Diet mobile application and use it daily for 5-minutes over 7-days. On Day 8, a mixed-form questionnaire will be used to evaluate acceptability, knowledge acquisition, engagement, usability using the System Usability Scale, and potential use in practice. After the first round, data will be compiled and reviewed to assess if revisions should be made. Based on the results from the first round, either the original or the revised versions will be presented in the second round to another 15 HCP following the same assessment method. Outcomes: The primary outcomes are face and content validation of the HCP-facing toolkit resources. The secondary outcomes are usability, acceptability, knowledge acquisition, engagement, and potential use in practice of the Portfolio Diet app. Data analyses: The Phase I feedback questionnaire for the HCP-facing Portfolio diet infographic and video consists of part A to assess content validity of the infographic and parts B and C to assess face validity of the infographic and video, respectively. In part A, the infographic has been divided into 6 parts, which HCP will be asked to rate individually on a scale of one to four with regard to its relevance. In parts B and C, HCP will be asked to rate a series of statements assessing content validity on a scale of 1-5, with 1 being "strongly disagree" and 5 being "strongly agree" for the infographic and video, respectively. After the first round, data will be compiled and reviewed with the study team. Lynn's method will be used to assess content validity of the HCP-facing infographic and video. If more than 30% of respondents rate any question in part A as irrelevant or rate 1-2 for any question in parts B or C, revisions will be made to the HCP-facing Portfolio diet toolkit resources as applicable. The second round of HCP will be presented either the original version or, if >30% rate the resources poorly, the revised version of the toolkit resources will be used and the HCP asked to follow the same method of assessing face and content validity. In Phase 2, after 8-days of using the Portfolio Diet app, a mixed-form questionnaire will be used to evaluate the acceptability, knowledge acquisition, engagement with the app, usability using the System Usability Scale (SUS) and the mHealth App Usability Questionnaire (MAUQ), and potential use in practice. The SUS is a validated usability questionnaire used in clinical settings to assess the usability of various systems and tools. The SUS includes 10 statements on a 5-point Likert scale, which is a psychometric scale frequently applied in health, and nutrition research, as well as in quality improvement testing, to assess the acceptability of systems and tools. The MAUQ is a recently developed questionnaire that focuses specifically on the usability of mobile health apps. It offers four versions catering to different app types (interactive or standalone) and target app users (patient or HCP), with the HCP-facing versions not yet validated. As such, data will be collected on the standalone HCP-facing version of the MAUQ in addition to the widely used SUS to contribute to validation. The SUS includes 10 statements rated on a 5-point Likert scale. The standalone, HCP-facing MAUQ includes 18 statements rated on a 7-point Likert scale. After the first round, data will be compiled and reviewed with the study team. If the calculated SUS is <70 or more than 30% of respondents indicate serious concerns, revisions will be made to the Portfolio Diet app. The second round of HCP will be presented either the original version or if >30% rate the Portfolio Diet app poorly, the revised version of the Portfolio Diet app to review following the same assessment method. Hypothesis: Validating the HCP-facing toolkit will demonstrate support for HCP knowledge and use of the Portfolio Diet and Portfolio Diet mobile application in clinical practice. Demonstrating that HCP rate the Portfolio Diet app as usable educational and has potential use in practice will further support clinical translation of the Portfolio Diet. This toolkit will also be used in the CIHR-funded Coronary Heart Effectiveness Assessment of the Portfolio diet in primary care (CHEAP) trial. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05915455
Study type Interventional
Source University of Toronto
Contact Laura Chiavaroli, PhD
Phone 4168268983
Email laura.chiavaroli@utoronto.ca
Status Recruiting
Phase N/A
Start date July 10, 2023
Completion date September 1, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)